# Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

> **NCT03130439** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 27 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT03130439
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-26
- **Primary completion:** 2021-08-18
- **Final completion:** 2022-01-30
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03130439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03130439, "Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03130439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*